Maslinic acid ameliorates inflammation via the downregulation of NF-κB and STAT-1

Cited 47 time in scopus
Metadata Downloads
Title
Maslinic acid ameliorates inflammation via the downregulation of NF-κB and STAT-1
Author(s)
Wonhwa Lee; J Kim; E K Park; J S Bae
Bibliographic Citation
Antioxidants, vol. 9, pp. 106-106
Publication Year
2020
Abstract
Maslinic acid (MA), a natural compound of the triterpenoid group derived from olive, prevents the generation of pro-inflammatory cytokines and oxidative stress. In human umbilical vein endothelial cells (HUVECs) treated with lipopolysaccharide (LPS), we characterized the effects of MA on the regulation of heme oxygenase (HO)-1, cyclooxygenase (COX-)2, and inducible nitric oxide synthase (iNOS). MA was tested in the lung tissues of LPS-treated mice, to determine its effect on levels of iNOS expression and representative inflammatory mediators such as interleukin (IL)-1 and tumor necrosis factor (TNF)-. We show that MA induced the expression of HO-1, reduced LPS-induced NF-κB-luciferase activity, and inhibited iNOS/NO and COX-2/PGE2, resulting in the downregulation of STAT-1 phosphorylation. Furthermore, our data show that MA induced the nuclear translocation of Nrf2, increased the binding of Nrf2 to ARE, and decreased IL-1 production in LPS-treated HUVECs. The MA-induced reduction in iNOS/NO expression was reversed by RNAi suppression of HO-1. In mice treated with LPS, MA significantly downregulated levels of iNOS in lung tissue and TNF- in the bronchoalveolar lavage fluid. Taken together, our findings indicate that MA exerts a critical anti-inflammatory effect by modulating iNOS via the downregulation of NF-κB and p-STAT-1. Thus, we propose that MA may be an ideal substance to treat inflammatory diseases.
Keyword
endotheliumiNOSmaslinic acidp-STAT-1
ISSN
2076-3921
Publisher
MDPI
Full Text Link
http://dx.doi.org/10.3390/antiox9020106
Type
Article
Appears in Collections:
1. Journal Articles > Journal Articles
Files in This Item:

Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.